Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03697564
Title Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Recruitment Suspended
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Hitendra Patel
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.